WO2018193011A1 - Procédés d'élimination de toxines bactériennes d'un fluide biologique - Google Patents

Procédés d'élimination de toxines bactériennes d'un fluide biologique Download PDF

Info

Publication number
WO2018193011A1
WO2018193011A1 PCT/EP2018/059979 EP2018059979W WO2018193011A1 WO 2018193011 A1 WO2018193011 A1 WO 2018193011A1 EP 2018059979 W EP2018059979 W EP 2018059979W WO 2018193011 A1 WO2018193011 A1 WO 2018193011A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
nil
residue
list
lps
Prior art date
Application number
PCT/EP2018/059979
Other languages
English (en)
Inventor
Alessandro Pini
Chiara Falciani
Luisa Bracci
Jlenia BRUNETTI
Leila QUERCINI
Original Assignee
Setlance S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Setlance S.R.L. filed Critical Setlance S.R.L.
Priority to JP2019556625A priority Critical patent/JP2020517329A/ja
Priority to US16/605,898 priority patent/US11104705B2/en
Priority to CN201880026047.1A priority patent/CN110546156B/zh
Priority to ES18720193T priority patent/ES2974691T3/es
Priority to EP18720193.4A priority patent/EP3612548B1/fr
Priority to PL18720193.4T priority patent/PL3612548T3/pl
Publication of WO2018193011A1 publication Critical patent/WO2018193011A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to methods for removing bacterial toxins such as lipopolysaccharide and lipoteichoic acid from a biological fluid.
  • a peptide selected from the list of KKIRVRLSA, RRIRVRLSA, KRIRVRLSA and RKIRVRLSA, is eovalently attached to a .solid support through its C-terminus, optionally with the interposition of a linker, and is used to capture the toxins.
  • This invention also relates to such derivatised solid supports and to cartridges, columns, and medical apparatuses comprising such derivatised solid supports.
  • Sepsis is a clinical syndrome caused by the body's immune and coagulation systems. Septic shock is a life-threatening condition that is characterized by low blood pressure despite adequate fluid replacement, and organ dysfunction or failure. Sepsis is an important cause of death in people of all ages (Perner et al, 2017).
  • sepsis was defined as a microbial infection that produces fever (or hypothermia), tachycardia, tachypnoea and blood leukocyte changes. Sepsis is now increasingly being considered a deregulated systemic inflammatory and immune response to microbial invasion that produces organ injury. Septic shock is defined as sepsis with hyperlactataemia and concurrent hypotension requiring vasopressor therapy, with in-hospital mortality rates approaching 30-50%.
  • Patients suffering from sepsis are usually treated with intravenous antibiotics, oxygen, fluids and drugs to stimulate the heart and to maintain an acceptable blood pressure level.
  • intravenous antibiotics, oxygen, fluids and drugs to stimulate the heart and to maintain an acceptable blood pressure level.
  • dialysis is used.
  • LPS Lipopolysaccharide
  • TLR4 Toll-like receptor 4
  • LTA lipoteichoic acid
  • TLR2 Toll-like receptor 2
  • TORAYMYXIN (Rocco and Klein 2014; Shoji et al, 1998) is a therapeutic strategy whereby polymyxin B (PMX), a typical antimicrobial peptide already used in clinic (Roscia et al, 2013), is immobilized to a polystyrene-derived fiber in a hemoperfusion device that is used to remove circulating LPS.
  • PMX polymyxin B
  • the PMX cartridge was created by covalently immobilizing PMX to polystyrene-derived fibers, which can then be used to filter blood externally using an extracorporeal circuit, thereby removing circulating LPS through its adsorption to the PMX cartridge.
  • the Alteco® LPS Adsorber (Ala-Kokko et al, 2011) is a medical device for extracorporeal removal of LPS during hemoperfusion.
  • the biotechnology of the product is based on a synthetic tailor-made peptide that selectively binds LPS found in the circulation of a septic patient.
  • WO2010038220 discloses the antibacterial peptide sequence KKIRVRLSA (M33) and its functional analogues, RRIRVRLSA, KRIRVRLSA and RKIRVRLSA provided in monomeric, dendrimeric structure and Multiple Antigen Peptide (MAP) forms, particularly in the form of Compound A below, and discloses the ability of M33 to neutralise LPS.
  • M33 antibacterial peptide sequence
  • MAP Multiple Antigen Peptide
  • WO2012010266 discloses that when the L-amino acids of M33 and its functional analogues are substituted with their relative D-amino acid counterpart, the resulting peptides still possess antibacterial activity.
  • M33- derived tetrabranched peptides wherein M33 is in either an all-L or in an all-D configuration, are known from Falciani et al. (2012) to bind both LTA and LPS in an assay whereby their biotinylated derivative is immobilized on streptavidin-coated cells (i.e. non covalently attached to a solid support).
  • EP 1789436 discloses MPA peptides having similar, but not identical, sequences to the M33 peptide and the M33 functional analogues of this invention, their synthesis via solid-phase synthesis (where the peptides, when bound to a solid support are fully side- chained protected) and their activity against LPS in a biacore assay (where the moiety bound to the solid support is LPS, but not the antimicrobial peptide).
  • Fig 1. depicts a composite resin of crosslinked hydroxyethylpolystyrene and polyethylene glycol.
  • Fig 2. depicts how a covalent bond is formed between the SulfolinkTM resin and a free thiol.
  • Fig. 3. depicts the HPLC profiles of a solution containing compound B before (A) and after (B) coupling to a SulfolinkTM resin.
  • Fig. 4 depicts the LPS content of a biological fluid before and after having been exposed to a resin derivatized with compound B (A) and to the same, underivatized, resin (B)
  • Fig. 5 depicts the LPS content of a biological fluid before and after having been exposed to a resin derivatised with compound B (A) and the same, underivatized, resin (B)
  • Fig. 6 depicts the protein electrophoresis profiles of a serum sample (A), a serum sample after having been in contact with a resin derivatised with compound B (B), a serum sample after having been in contact with a resin derivatised with compound A (C), and the references values for such proteins (D)
  • Fig. 7 depicts the LTA content of a biological fluid before and after having been exposed to a resin derivatised with compound B (A) and the same, underivatized, resin (B) DETAILED DESCRIPTION OF THE INVENTION
  • Such derivatized solid support can also be used to remove LTA from the biological fluid.
  • a method for the removal of a bacterial toxin selected from the list of LPS and LTA from a biological fluid comprising contacting the biological fluid with a peptide selected from the list of KKIRVRLSA, RRIRVRLSA, KRIRVRLSA and RKIRVRLSA, which peptide is covalently attached to a solid support through its C-terminus, optionally with the interposition of a linker, and wherein all amino acids of the peptide are either in the L- or the D-configuration.
  • all amino acids of the peptide selected from the list of KKIRVRLSA, RRIRVRLSA, KRIRVRLSA and RKIRVRLSA are in the L- configuration.
  • all amino acids of the peptide selected from the list of KKIRVRLSA, RRIRVRLSA, KRIRVRLSA and RKIRVRLSA are in the D- configuration.
  • the peptide-linker moiety is a radical of the formula below
  • Ri— , R 2 — , R3— , R4— , R5— , Re— , R7— and Rs— can be the same or different and are selected from KKIRVRLSA— , RRIRVRLSA— , KRIRVRLSA— and RKIRVRLSA— ;
  • Xi, X 2 , X 3 , X4, X5, ⁇ and X7 are the same or different and are an at least bifunctional residue;
  • n, m, p, q, t, v and w can be the same or different and can be nil or 1 , and at least one of m, n, p and q is 1 , with the proviso that if t is nil, then n and m are nil and at least one of p and q are 1 , that if v is nil then p and q are nil and at least one of m and n are 1 and that if w is nil then v is nil and at least one of m and n are 1 ;
  • Y is a bond or a spacer.
  • Xi, X 2 , X 3 , X4, X5, X 6 and X7 are the same or different and each comprise at least two functional amino groups.
  • Xi, X 2 , X 3 , X4, X5, X 6 and X7 are the same or different and are selected from a lysine residue, an ornithine residue, a norlysine residue, an amino alanine residue and a diaminopropionic acid residue.
  • At least one of Ri— , R 2 — , R3— R4— , R5— , Re— , R7— and Rs— is KKIRVRLSA—
  • each of Ri— , R 2 — , R3— R4— , R5— , Re— , R7— and Rs— is KKIRVRLSA—
  • Y is selected from the list of an amino acid residue and a peptide.
  • Y is selected from the list of an amino acid residue, a dipeptide, a tripeptide, a tetrapeptide, a pentapeptide, an hexapeptide, an octapeptide, a nonapeptide and a decapeptide.
  • Y is selected from the list of a beta-alanine residue, an N-(PEG) y -CH 2 -CH 2 -C(0) residue wherein l ⁇ y ⁇ 1 1 , a cysteine residue and a peptide comprising such residue.
  • the peptide of the previous embodiment is selected from the list of, a dipeptide, a tripeptide, a tetrapeptide, a pentapeptide, an hexapeptide, an octapeptide, a nonapeptide, a decapeptide.
  • y is selected from the list of 1 ,2,3,4,5,6,7,8,9, 10 and 1 1.
  • w is nil
  • v is nil
  • t is 1
  • m is 1
  • n is 1.
  • w is nil
  • v is nil
  • t is 1
  • m is 1
  • n is 1
  • Xi, X 2 and X5 each are a lysine residue.
  • w is nil
  • v is nil
  • t is 1
  • m is 1
  • n is 1 and at least one of Ri— , R 2 — , R 3 — and R 4 — , is KKIRVRLSA—.
  • w is nil
  • v is nil
  • t is 1
  • m is 1 and n is 1 and each of Ri— , R 2 — , R 3 — and R 4 — , is KKIRVRLSA—.
  • the solid support is porous.
  • the solid support is a crosslinked agarose resin.
  • the solid support is a composite resin of crosslinked hydroxy ethylpolystyrene and polyethylene glycol.
  • the biological fluid is selected from the list of serum, plasma and blood.
  • a medical apparatus comprising the solid support of the second aspect of this invention or the item of the third aspect of this invention.
  • the medical apparatus is a medical apparatus for the removal of a bacterial toxin selected from the list of LPS and LTA from biological fluids.
  • a fifth aspect of this invention there is provided the use of the medical apparatus of the fourth aspect of this invention for the removal of a bacterial toxin selected from the list of LPS and LTA from biological fluids.
  • This resin a is a composite of low cross-linked hydroxyethylpolystyrene and 3000-4000 MW polyethylene glycol, which has been terminally functionalized with amino groups. (Fig. 1)
  • Peptide synthesis was carried out on an automated synthesizer Syro (MultiSynTech, Witten, Germany) using 9-fluorenylmethoxycarbonyl (Fmoc) chemistry and 0-(benzotriazol- 1 -yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (HBTU)/ 1,3- isopropylethylamine (DIPEA) activation.
  • Side-chain-protecting groups were tert- butoxycarbonyl for Lys, 2,2,4,6, 7-pentamethyldihydrobenzofuran-5-sulfonyl for Arg, and tert-butyl ether for Ser.
  • the first amino acid was Fmoc-PAla-OH.
  • Two consecutive coupling steps with Fmoc-Lys(Fmoc)-OH were used to build the lysine core, followed by sequential addition of Fmoc amino acids to complete the peptide KKIRVRLSA.
  • Compound A on resin was side-chain deprotected by treatment with trifluoroacetic acid containing water and triisopropylsilane (95:2.5:2.5).
  • the peptidyl-resin was then washed four times with DCM, four times with MeOH, three times with acetic acid 1M, four times with H20 and four times with MeOH.
  • Compound B was produced by solid-phase synthesis through standard Fmoc chemistry with a Syro multiple peptide synthesizer (MultiSynTech, Witten, Germany).
  • the peptide was synthesized on TentaGel S RAM resin with Fmoc -NH-Cys(Trt)-COOH as first amino acid in C-terminus, Fmoc-NH-PEG(4)-CH2-CH2-COOH was added in second coupling step, then Fmoc-Lys(Fmoc)-OH was added twice to build the tetrameric core.
  • Fmoc amino acids to complete the peptide KKIRVRLSA.
  • Compound B was attached via its sulfhydryl to a SulfolinkTM resin, which is a cross linked agarose resin, as depicted in Fig. 2.
  • Compound B (1 mg/ml) diluted in 4 ml was resuspended and incubated for 30 minutes at room temperature in Coupling Buffer (50 mM Tris, 5 mM EDTA-Na; pH 8.5).
  • Coupling Buffer 50 mM Tris, 5 mM EDTA-Na; pH 8.5.
  • the SulfoLinkTM Resin (SulfoLink® Immobilization Kit for Peptides, Pierce Biotechnology, Rockford, Illinois, USA) in its cartridge/column (5 ml column, 1 cm diameter, volume of the resin 2 ml) was resuspended by mixing, and the storage buffer was removed by centrifuging at 1,000 x g for 1 minute positioning the column in a 15 ml collection tube.
  • the column was washed and centrifuged for three times. Then, the column was washed with Coupling Buffer 2 ml and centrifuged. 50 mM cysteine in Coupling Buffer was then applied to the column and mixed for 45 minutes at room temperature, in order to block unreacted binding sites. After further centrifugation, the column was allowed to drain.
  • Example 4 Resin-bound compound B removes LPS from a biological fluid and does not significantly alter the serum protein content
  • the loaded resin was able to remove 85% of E. coli LPS from serum, whereas the unloaded resin did not remove LPS at all.
  • Fig. 6A and 6B which respectively depict the capillary electrophoresis profiles of sera before and after passage onto the compound B- loaded resin such passage does not significantly alter the serum protein content.
  • Example 5 Resin-bound compound A removes LPS from a biological fluid and does not significantly alter the serum protein content
  • Fig. 6A and 6C which respectively depict the capillary electrophoresis profiles of sera before and after passage onto the compound A- loaded resin, such passage does not significantly alter the serum protein content.
  • a standard curve (0.1-1 EU/ml) was prepared using a control standard endotoxin from Escherichia coli (0111 :B4) in endotoxin- free water, and serially diluted. Serum samples were diluted 50 and 100 fold in endotoxin- free water. Each sample was processed in duplicate.
  • microplate was equilibrated in a heating block for 10 minutes at 37°C. Then,
  • LAL Limulus Amebocyte Lysate
  • the LTA content of a sample can be readily determined by the use of commercial kits to that effect.
  • kits is the Antibody Research Corporation (St.Charles, Missouri) LTA ELISA kit.
  • the sample is added to micro-plate wells pre-coated with Lipoteichoic acids antibody. After incubation and washing, a lipoteichoic acids detection antibody labeled with biotin is added. After appropriate incubation, a streptavidin- horse radish peroxidase (HRP) conjugate is added followed by incubation and washing to remove the uncomplexed enzymes. After addition of a chromogenic 3,3 ',5,5'- tetramethylbenzidine (TMB) solution the sample is incubated for 5 minutes.
  • HRP horse radish peroxidase
  • the HRP enzyme reaction is stopped by addition of a sulphuric acid solution.
  • the intensity of color developed is proportional to the concentration of the Lipoteichoic acids present in the sample and read at 450nM using a plate reader. Concentration of Lipoteichoic acid in the sample is determined by interpolating the absorbance value in the standard curve.
  • a standard curve (7.8-500 pg/ml) was prepared using a control standard lipoteichoic acid from S. aureus in Sample/Standard dilution buffer, and serially diluted.
  • Samples were diluted 2 and 10 fold in Sample/Standard dilution buffer. Each sample was processed in duplicate.
  • microplate was washed two times before adding standard, sample and control
  • Biotin-detection Antibody working solution 100 of Biotin-detection Antibody working solution was added into the above wells and incubated for 60 minutes at 37°C.
  • the plate was washed three times with Wash Buffer.
  • TMB substrate solution 90 ⁇ , of TMB substrate solution was added to each well. The plate was incubated for 15-30 minutes at 37°C in dark. In the end, 50 ⁇ , of Stop Solution was added. The absorbance at 450nm was measured on a plate reader (Ascent Software). The LTA concentration was calculated on the base of standard curve obtained as described above.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)

Abstract

La présente invention concerne des procédés d'élimination de toxines bactériennes telles que le lipopolysaccharide et l'acide lipotéichoïque à partir d'un fluide biologique. Dans un tel procédé, un peptide, choisi dans la liste des KKIRVRLSA, RRIRVRLSA, KRIRVRLSA et RKIRVRLSA, est fixé de manière covalente à un support solide par son extrémité C, éventuellement avec l'interposition d'un lieur, et est utilisé pour capturer les toxines. La présente invention concerne également de tels supports solides dérivatisés et des cartouches, des colonnes et des appareils médicaux comprenant de tels supports solides dérivatisés.
PCT/EP2018/059979 2017-04-20 2018-04-19 Procédés d'élimination de toxines bactériennes d'un fluide biologique WO2018193011A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2019556625A JP2020517329A (ja) 2017-04-20 2018-04-19 生体液から細菌毒素を除去するための方法
US16/605,898 US11104705B2 (en) 2017-04-20 2018-04-19 Methods for removing bacterial toxins from a biological fluid
CN201880026047.1A CN110546156B (zh) 2017-04-20 2018-04-19 从生物流体中除去细菌毒素的方法
ES18720193T ES2974691T3 (es) 2017-04-20 2018-04-19 Métodos para eliminar toxinas bacterianas de un fluido biológico
EP18720193.4A EP3612548B1 (fr) 2017-04-20 2018-04-19 Procédés d'élimination de toxines bactériennes d'un fluide biologique
PL18720193.4T PL3612548T3 (pl) 2017-04-20 2018-04-19 Sposoby usuwania toksyn bakteryjnych z płynu biologicznego

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17167353.6 2017-04-20
EP17167353.6A EP3392265A1 (fr) 2017-04-20 2017-04-20 Procédés d'élimination de toxines bactériennes d'un fluide biologique

Publications (1)

Publication Number Publication Date
WO2018193011A1 true WO2018193011A1 (fr) 2018-10-25

Family

ID=58701388

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/059979 WO2018193011A1 (fr) 2017-04-20 2018-04-19 Procédés d'élimination de toxines bactériennes d'un fluide biologique

Country Status (7)

Country Link
US (1) US11104705B2 (fr)
EP (2) EP3392265A1 (fr)
JP (1) JP2020517329A (fr)
CN (1) CN110546156B (fr)
ES (1) ES2974691T3 (fr)
PL (1) PL3612548T3 (fr)
WO (1) WO2018193011A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024127218A1 (fr) * 2022-12-12 2024-06-20 Medica S.P.A. Procédé de fabrication d'un dispositif et dispositif de traitement de fluides

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111233714B (zh) * 2020-03-18 2022-04-08 滨海吉尔多肽有限公司 一种maps多肽的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006440A1 (fr) * 1997-07-31 1999-02-11 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Nouveaux peptides synthetiques possedant des proprietes antimicrobiennes et de neutralisation d'endotoxines et permettant de lutter contre le syndrome de septicemie
EP1232754A2 (fr) * 2001-02-14 2002-08-21 Commonwealth Biotechnologies, Inc. Utilisation de peptides cationiques en hélice pour le traitement de la septicémie et pour détecter et éliminer les endotoxines
EP1789436A1 (fr) 2004-07-13 2007-05-30 Universita' Degli Studi di Siena Peptides antibactériens et analogues de ceux-ci
WO2010038220A1 (fr) 2008-10-05 2010-04-08 Università Degli Studi Di Siena Séquences peptidiques, leur forme ramifiée et leur utilisation dans le cadre d'applications anti-microbiennes
WO2012010266A1 (fr) 2010-07-23 2012-01-26 Setlance S.R.L. Peptide antimicrobien, formes ramifiées de celui-ci et leur utilisation dans le traitement des infections bactériennes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE526038C2 (sv) * 2002-07-08 2005-06-21 Gambro Lundia Ab Polymeraffinitetsmatris, förfarande för framställning därav och anvädning därav

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006440A1 (fr) * 1997-07-31 1999-02-11 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Nouveaux peptides synthetiques possedant des proprietes antimicrobiennes et de neutralisation d'endotoxines et permettant de lutter contre le syndrome de septicemie
EP1232754A2 (fr) * 2001-02-14 2002-08-21 Commonwealth Biotechnologies, Inc. Utilisation de peptides cationiques en hélice pour le traitement de la septicémie et pour détecter et éliminer les endotoxines
EP1789436A1 (fr) 2004-07-13 2007-05-30 Universita' Degli Studi di Siena Peptides antibactériens et analogues de ceux-ci
WO2010038220A1 (fr) 2008-10-05 2010-04-08 Università Degli Studi Di Siena Séquences peptidiques, leur forme ramifiée et leur utilisation dans le cadre d'applications anti-microbiennes
WO2012010266A1 (fr) 2010-07-23 2012-01-26 Setlance S.R.L. Peptide antimicrobien, formes ramifiées de celui-ci et leur utilisation dans le traitement des infections bactériennes

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
ALA-KOKKO TI; LAURILA J; KOSKENKARI J: "A new endotoxin adsorber in septic shock: observational case series", BLOOD PURIF., vol. 34, 2011, pages 303 - 9
ANNA GUSTAFSSON ET AL: "LPS interactions with immobilized and soluble antimicrobial peptides", SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, vol. 70, no. 3, 19 January 2010 (2010-01-19), GB, pages 194 - 200, XP055409912, ISSN: 0036-5513, DOI: 10.3109/00365511003663622 *
CHIARA FALCIANI ET AL: "Isomerization of an Antimicrobial Peptide Broadens Antimicrobial Spectrum to Gram-Positive Bacterial Pathogens", PLOS ONE, vol. 7, no. 10, 2 October 2012 (2012-10-02), pages e46259, XP055410370, DOI: 10.1371/journal.pone.0046259 *
COHEN J; ASLAM M; PUSEY CD; RYAN CJ: "Protection from endotoxemia: a rat model of plasmapheresis and specific adsorption with polymyxin B", J INFECT DIS, vol. 155, no. 4, 1987, pages 690 - 5
COSTA F; CARVALHO IF; MONTELARO RC; GOMES P; MARTINS MCL, ACTA BIOMATERIALIA, vol. 7, 2011, pages 1431 - 1440
FABOLA COSTA ET AL: "Covalent immobilization of antimicrobial peptides (AMPs) onto biomaterial surfaces", ACTA BIOMATERIALIA, ELSEVIER, AMSTERDAM, NL, vol. 7, no. 4, 1 November 2010 (2010-11-01), pages 1431 - 1440, XP028366339, ISSN: 1742-7061, [retrieved on 20101105], DOI: 10.1016/J.ACTBIO.2010.11.005 *
FALCIANI, C.; LOZZI, L.; POLLINI, S.; LUCA, V.; CARNICELLI, V.; BRUNETTI, J.; LELLI, B.; BINDI, S.; SCALI, S.; DI GIULIO, A.: "Isomerization of an antimicrobial peptide broadens antimicrobial spectrum to gram-positive bacterial pathogens", PLOS ONE, vol. 7, 2012, pages e46259
GUSTAFSSON A; OLIN AI; LJUNGGREN L, SCANDINAVIAN JOURNAL OF CLINICAL AND LABORATORY INVESTIGATION, vol. 70, 2010, pages 194 - 200
HOTCHKISS RS; MOLDAWER LL; OPAL SM; REINHART K; TUMBULL IR; VINCENT JL: "Sepsis and septic shock", NAT REV DIS PRIMERS, vol. 2, 2016, pages 16045
IANARO A; TERSIGNI M; D'ACQUISTO F: "New insight in LPS antagonist", MINI REV MED CHEM., vol. 9, 2009, pages 306 - 17, XP009117995
KANG SS; SIM JR; YUN CH; HAN SH: "Lipoteichoic acids as a major virulence factor causing inflammatory responses via Toll-like receptor 2", ARCH PHARM RES., vol. 39, 2016, pages 1519 - 1529, XP036106751, DOI: doi:10.1007/s12272-016-0804-y
LAKSHMIKANTH CL; JACOB SP; CHAITHRA VH; DE CASTRO-FARIA-NETO HC; MARATHE GK: "Sepsis: in search of cure", INFLAMM RES., vol. 65, 2016, pages 587 - 602, XP035993863, DOI: doi:10.1007/s00011-016-0937-y
PERNER A; RHODES A; VENKATESH B; ANGUS DC; MARTIN-LOECHES I; PREISER JC; VINCENT JL; MARSHALL J; REINHART K; JOANNIDIS M: "Sepsis: frontiers in supportive care, organisation and research", INTENSIVE CARE MED., vol. 43, 2017, pages 496 - 508, XP036192249, DOI: doi:10.1007/s00134-017-4677-4
ROCCO; KLEIN: "Polymyxin B hemoperfusion: a mechanistic perspective", CRITICAL CARE, vol. 18, 2014, pages 309, XP021208506, DOI: doi:10.1186/cc13912
ROSCIA, G.; FALCIANI, C.; BRACCI, L.; PINI, A.: "The development of antimicrobial peptides as new antibacterial drugs", CURR PROTEIN PEPT SCI., vol. 14, 2013, pages 641 - 649
SHOJI H; TANI T; HANASAWA K; KODAMA M: "Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: designing and antiendotoxin efficacy in the clinical application", THERAPEUTIC APHERESIS, vol. 2, 1998, pages 3 - 12

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024127218A1 (fr) * 2022-12-12 2024-06-20 Medica S.P.A. Procédé de fabrication d'un dispositif et dispositif de traitement de fluides

Also Published As

Publication number Publication date
CN110546156A (zh) 2019-12-06
CN110546156B (zh) 2023-12-22
ES2974691T3 (es) 2024-07-01
JP2020517329A (ja) 2020-06-18
PL3612548T3 (pl) 2024-07-15
EP3612548A1 (fr) 2020-02-26
US20200048307A1 (en) 2020-02-13
US11104705B2 (en) 2021-08-31
EP3612548C0 (fr) 2024-04-03
EP3392265A1 (fr) 2018-10-24
EP3612548B1 (fr) 2024-04-03

Similar Documents

Publication Publication Date Title
JP4037525B2 (ja) 新規抗菌性ペプチド
EP2021374B1 (fr) Matrice tridimensionnelle biocompatible utilisée pour l'immobilisation de substances biologiques
EP2058335B1 (fr) Matrice tridimensionnelle biocompatible pour l'immobilisation de substances biologiques
ES2737731T5 (es) Medios de cromatografía de afinidad para la eliminación de anticuerpos anti-A y/o anti-B
WO2013027796A1 (fr) Peptide de liaison à l'immunoglobuline g et procédé de détection et d'épuration d'immunoglobuline g mettant en œuvre un tel peptide
KR100960743B1 (ko) 신규 펩티드, 신규 흡착재, 흡착기 및 흡착방법
RU2008120027A (ru) Анти-addl моноклональное антитело и его применение
RU2009135802A (ru) Способ активации хелперных т-клеток и композиция для применения в данном способе
KR100445644B1 (ko) 면역글로블린과그의복합체를위한흡착제,흡착방법그리고흡착장치
US11104705B2 (en) Methods for removing bacterial toxins from a biological fluid
WO2008151847A1 (fr) Peptides de liaison aux autoanticorps et leur utilisation pour le traitement de maladies vasculaires
JPWO2018061509A1 (ja) 環状ペプチド、アフィニティクロマトグラフィー担体、標識化抗体、抗体薬物複合体および医薬製剤
US20060263835A1 (en) Identification of agonistic autoantibodies
US20110082421A1 (en) Receptor-Based Blood Detoxification System
WO2007060769A1 (fr) Liant de lipopolysaccharide ou de lipide a, et nouveau peptide
CZ2004122A3 (cs) Glykopeptidy
Wade et al. Identification of Functional Domains in Efb, a Fibrinogen Binding Protein ofStaphylococcus aureus
JP2015515264A (ja) 疾患の処置のためのキメラタンパク質
JP6259245B2 (ja) 免疫グロブリンＧに対する親和性を有するペプチド及びそれを用いたＩｇＧ型抗体吸着材
Levashov et al. Affinity sorbent based on tryptophyl-threonyl-tyrosine for binding of the immunoglobulins G: sorption characteristics and aspects of practical application
CN103130872A (zh) 吸附剂、固相载体及精制方法
CN107827961B (zh) 用于金黄色葡萄球菌Staphopain B蛋白检测的B细胞抗原表位肽及其试剂盒
RU2389022C2 (ru) Сорбент для удаления иммуноглобулинов
RU2356576C1 (ru) СИНТЕТИЧЕСКИЙ АНТИГЕН, ОБЛАДАЮЩИЙ СПОСОБНОСТЬЮ СВЯЗЫВАТЬ АУТОАНТИТЕЛА К β1-АДРЕНОРЕЦЕПТОРУ
JP6864882B2 (ja) 免疫グロブリンＧに対する親和性を有するペプチドを担持したＩｇＧ型抗体吸着材

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18720193

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019556625

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018720193

Country of ref document: EP

Effective date: 20191120